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Articles
Clinical efficacy and safety of a light mask for prevention of 
dark adaptation in treating and preventing progression of 
early diabetic macular oedema at 24 months (CLEOPATRA): 
a multicentre, phase 3, randomised controlled trial
Sobha Sivaprasad, Joana C Vasconcelos, A Toby Prevost, Helen Holmes, Philip Hykin, Sheena George, Caroline Murphy, Joanna Kelly, 
Geoffrey B Arden, on behalf of the CLEOPATRA Study Group*
Summary
Background We aimed to assess 24-month outcomes of wearing an organic light-emitting sleep mask as an 
intervention to treat and prevent progression of non-central diabetic macular oedema.
Methods CLEOPATRA was a phase 3, single-blind, parallel-group, randomised controlled trial undertaken at 
15 ophthalmic centres in the UK. Adults with non-centre-involving diabetic macular oedema were randomly assigned 
(1:1) to wearing either a light mask during sleep (Noctura 400 Sleep Mask, PolyPhotonix Medical, Sedgefield, UK) 
or a sham (non-light) mask, for 24 months. Randomisation was by minimisation generated by a central web-based 
computer system. Outcome assessors were masked technicians and optometrists. The primary outcome was the 
change in maximum retinal thickness on optical coherence tomography (OCT) at 24 months, analysed using a linear 
mixed-effects model incorporating 4-monthly measurements and baseline adjustment. Analysis was done using the 
intention-to-treat principle in all randomised patients with OCT data. Safety was assessed in all patients. This trial is 
registered with Controlled-Trials.com, number ISRCTN85596558.
Findings Between April 10, 2014, and June 15, 2015, 308 patients were randomly assigned to wearing the light mask 
(n=155) or a sham mask (n=153). 277 patients (144 assigned the light mask and 133 the sham mask) contributed to the 
mixed-effects model over time, including 246 patients with OCT data at 24 months. The change in maximum retinal 
thickness at 24 months did not differ between treatment groups (mean change –9·2 μm [SE 2·5] for the light mask 
vs –12·9 μm [SE 2·9] for the sham mask; adjusted mean difference –0·65 μm, 95% CI –6·90 to 5·59; p=0·84). 
Median compliance with wearing the light mask at 24 months was 19·5% (IQR 1·9–51·6). No serious adverse events 
were related to either mask. The most frequent adverse events related to the assigned treatment were discomfort on 
the eyes (14 with the light mask vs seven with the sham mask), painful, sticky, or watery eyes (14 vs six), and sleep 
disturbance (seven vs one). 
Interpretation The light mask as used in this study did not confer long-term therapeutic benefit on non-centre-
involving diabetic macular oedema and the study does not support its use for this indication.
Funding The Efficacy and Mechanism Evaluation Programme, a Medical Research Council and National Institute for 
Health Research partnership.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Diabetic macular oedema is the most common cause of 
moderate visual loss in people with diabetes mellitus.1 The 
location and quantity of increased retinal thickness due to 
diabetic macular oedema can be recorded objectively using 
optical coherence tomography (OCT). All OCT devices 
have an in-built Early Treatment Diabetic Retinopathy 
Study (ETDRS) grid with nine zones (subfields) centred on 
the fovea (figure 1). Centre-involving diabetic macular 
oedema is defined as presence of oedema in zone 1. 
Non-centre-involving diabetic macular oedema is oedema 
restricted to one or more of zones 2–9. The zone of 
maximum retinal thickness can be monitored over time to 
assess the course of disease. However, diabetic macular 
oedema can appear and disappear at any zone and might 
represent worsening of disease despite resolution of 
oedema at the zone of maximum retinal thickness. 
Therefore, response to treatment must be assessed 
objectively by looking at several variables, including 
change in retinal thickness in all nine zones as well as total 
macular volume.2 Not all patients with centre-involving 
diabetic macular oedema have impaired vision. Therefore, 
progression of diabetic macular oedema to the centre is 
better measured as an increase in central subfield 
thickness (zone 1) than change in visual acuity.
Approximately 8% of people with diabetes have 
centre-involving diabetic macular oedema and a further 
8% have non-central diabetic macular oedema. Standard 
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treatments for people with centre-involving diabetic 
macular oedema are invasive and include repeated 
intravitreal injections of anti-vascular endothelial growth 
factor (anti-VEGF) agents, use of steroids, or laser treat-
ment.3,4 Less invasive treatment will save patients from 
these procedures and have a major positive effect on 
health-care spending. Furthermore, there is an unmet 
need for preventive and treatment options for non-central 
diabetic macular oedema to prevent potential visual 
morbidity due to disease progression.5
During dark adaptation, normal rod photoreceptors in 
the retina consume nearly all the oxygen available to the 
eye.6 In patients with diabetes the retinal oxygen supply is 
compromised and the hypoxic status during dark periods 
might exacerbate microvascular changes.7 This idea has 
been substantiated by the fact that oxygen supplementation 
alleviates diabetic macular oedema in the short term.8 
Sivaprasad and Arden7 postulated that if dark adaptation 
could be prevented, diabetic macular oedema and diabetic 
retinopathy might be alleviated by decreasing the oxygen 
demand. Since dark adaptation in man only happens at 
night during sleep, sleeping in an environment illuminated 
with 500–505 nm light should suppress rods and prevent 
or reverse diabetic macular oedema. A proof-of-concept 
study in 12 patients who slept at night using a mask 
containing a chemi luminescent source that exposed 
Research in context
Evidence before this study
We searched PubMed from database inception until 
Sept 1, 2017, and abstracts from annual meetings of the 
Association for Research in Vision and Ophthalmology until 
2017, with the terms “lightmasks” AND “diabetic retinopathy” 
OR “diabetic macular oedema” for reports of randomised 
controlled trials published in English only. We identified no 
randomised trials. Non-centre-involving diabetic macular 
oedema can progress to the centre of the macula and cause 
visual impairment. Standard treatment for centre-involving 
diabetic macular oedema with visual impairment is repeated 
intravitreal injections with anti-vascular endothelial growth 
factor agents. Other treatment options include macular laser 
and intravitreal steroids. Many investigators have evaluated 
less invasive treatment options for non-centre-involving 
macular oedema to delay or prevent disease progression but 
have been unsuccessful. Rod photoreceptors in the retina 
consume a maximum amount of oxygen during dark 
adaptation. In diabetes, the resultant hypoxia can contribute 
to development and progression of diabetic macular oedema 
and diabetic retinopathy. Two short-term clinical trials showed 
that wearing light masks emitting 500–505 nm light through 
the eyelids to decrease dark adaptation reduced the rate of 
progression of diabetic retinopathy and early diabetic macular 
oedema, respectively. In an abstract, 45 healthy volunteers 
wore an organic light-emitting sleep mask to prevent dark 
adaptation and showed no safety concerns at 4 months. 
24% withdrew from the intervention before 1 month because 
of light intolerance and sleep disturbance. In another abstract, 
a light-emitting sleep mask to prevent dark adaptation in 
six patients with refractory clinically significant diabetic 
macular oedema showed good acceptability  and tolerance for 
five patients at 6 months. As far as we know, no randomised 
controlled trials have been done to assess the role of light 
masks during sleep as a novel treatment for patients with 
non-central diabetic macular oedema. A study assessing the 
safety and acceptability of an organic light-emitting sleep 
mask (Noctura 400 Sleep Mask, PolyPhotonix Medical, 
Sedgefield, UK) in healthy volunteers (n=45) and patients with 
diabetic macular oedema (n=15) reported no clinically relevant 
safety issues at 4 months. 16 withdrew from the study, 
eight before month 1. The mean change in maximum retinal 
thickness in eyes with diabetic macular oedema at 4 months 
was −12·00 μm (range −28·80 to 4·80). A recent publication 
also showed good compliance with the light masks in diabetic 
macular oedema at 6 months.
Added value of this study
The CLEOPATRA trial is, to our knowledge, the first randomised 
controlled trial to evaluate the effect of an organic 
light-emitting sleep mask as a treatment option for 
non-centre-involving diabetic macular oedema. The 24-month 
follow-up period provides data for efficacy, safety, and 
compliance of wearing these light masks for this condition. The 
results show that the light masks as used in this study did not 
provide any discernible clinical benefit. No differences were 
recorded between wearing and not wearing these light masks 
in the change in thickness in the zone of maximum retinal 
thickness, total macular volume, progression of the oedema to 
the centre, proportion of patients requiring standard treatment 
for diabetic macular oedema, and progression of diabetic 
retinopathy. The analysis of compliance highlighted that 
wearing these light masks over 24 months might also not be a 
sustainable option, as compliance decreased over time. 
The results of the study were not accounted for by 
non-compliance of wearing the light masks. No light 
mask-related serious adverse events were recorded.
Implications of all the available evidence
The CLEOPATRA study provides evidence that the light mask 
offered to prevent dark adaptation is not recommended as a 
treatment option for non-centre-involving diabetic macular 
oedema. Although earlier studies showed short-term 
improvement in diabetic oedema and diabetic retinopathy 
using 505 nm light masks, our study shows that compliance 
wearing the light masks during sleep is challenging and is 
therefore not a sustainable option. Since laboratory-based 
evidence of the role of photoreceptors in diabetic retinopathy is 
increasing, there remains an unmet need to translate this idea 
into interventions in patients. 
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one eye only to light for 3 months showed that the 
treatment had no safety issues, was acceptable to patients, 
and both colour vision and microaneurysm count 
improved.9 A second study used light-emitting diodes 
(LEDs) to illuminate one eye with 505 nm light during 
sleep in 40 patients with bilateral diabetic macular 
oedema.10 34 patients completed the study and an improve-
ment in retinal function and a decrease in retinal thickness 
at 6 months was noted. Based on these observations, the 
Noctura 400 Sleep Mask (PolyPhotonix Medical, Sedgefield, 
UK) was CE-approved for the treatment of diabetic 
retinopathy. The long-term effect ive ness, compliance, and 
safety of light masks are unknown. We did a phase 3 clinical 
trial (CLEOPATRA) to investigate whether offering the 
light mask to wear over closed eyelids during sleep at night 
for 24 months could treat and prevent the progression of 
non-centre-involving diabetic macular oedema.
Methods
Study design and patients
The CLEOPATRA study is a phase 3, multicentre, single-
blind, parallel-group, randomised controlled trial. Patients 
were recruited from 15 ophthalmic centres at UK National 
Health Service (NHS) hospitals. We included adults (aged 
≥18 years) with type 1 or 2 diabetes mellitus and clinical 
and OCT evidence of retinal thickening in at least one non-
central ETDRS zone due to diabetic macular oedema with 
best-corrected visual acuity of more than 55 ETDRS letters, 
equivalent to 6/18 Snellen. We permitted previous macular 
laser therapy, intravitreal steroids, or anti-VEGF agents 
provided the last treatment was given at least 4 months 
before randomisation.11
Exclusion criteria for eyes were centre-involving diabetic 
macular oedema, other causes of macular oedema, or 
coexistent ocular disease that affected or might affect 
visual acuity or prevent treatment delivery. We also 
excluded eyes with active proliferative diabetic retinopathy 
or that were treated previously with panretinal photo-
coagulation. Systemic exclusion criteria included history of 
insomnia or any other sleep disturbances.
The study was granted approval by the National Research 
Ethics Committee Service London—Dulwich (13/LO/0145). 
Trial Steering and Data Monitoring Committees provided 
independent oversight. A representative of the manu-
facturer was a non-voting member of the Trial Steering 
Committee. All eligible patients gave written informed 
consent before study participation.
Randomisation and masking
We randomly allocated eligible patients (1:1) to wear 
during sleep either a light mask or a sham (non-
light) mask, using the method of minimisation, 
concealed before allocation, stratified by HbA1c (<8% 
[63·89 mmol/mol] or ≥8% [63·90 mmol/mol]), perifoveal 
(ETDRS zones 6–9) versus parafoveal (ETDRS zones 2–5) 
baseline thickness in excess of 320 μm in the perifoveal 
or parafoveal zones, and study site. For patients with the 
same baseline thickness in excess of 320 μm in the 
perifoveal or parafoveal zones, the parafoveal zone was 
chosen. Randomisation was done by collaborating site 
investi gators via the King’s Clinical Trials Unit web-based 
randomisation service. Patients and examining clinicians 
were aware of the study allocation because of the nature 
of the intervention. Patients assigned the sham mask had 
the option of not using it because it became apparent 
early in the study that many patients were not using it. 
Outcome assessors including OCT technicians, optomet-
rists, and graders at the independent reading centre 
based at the Gloucestershire Eye Unit (Gloucester, UK) 
were unaware of treatment allocation.
Procedures
The light mask used in the intervention arm was the 
Noctura 400 Sleep Mask (PolyPhotonix Medical). This 
CE-certified class 2a device is designed to deliver 
blue-green light through closed eyelids. The light mask 
consists of two battery-operated organic LEDs inserted 
within a fabric mask and placed over the patients’ eyes 
using an adjustable velcro strap. It is operational for a 
maximum of 8 h therapy per night. The lifetime of the 
light mask is 84 days, after which time a replacement 
mask is required. Based on calculations done by the 
manufacturer, the light mask provides a luminance of 
75 photopic cd/m² (± 10%), equating to 186 scotopic cd/m². 
After considering light attenuation through closed 
eyelids and pupillary diameter, these light masks are 
expected to cause 40% reduction in rod-circulating 
current. The decay of mask output over its lifetime is also 
maintained within 10% of the desired output. The light 
intensity we used is approximately six orders of mag-
nitude less than for threshold toxicity and two orders 
below that which causes a 1% change in the melatonin 
cycle that drives circadian rhythms.
The light mask records automatically when it is being 
worn, providing an accurate measure of compliance. These 
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Figure 1: ETDRS grid within OCT devices
The ETDRS grid divides the macula into nine zones in the right and left eye, with 
zone 1 the central subfield, zones 2–5 parafoveal zones, and zones 6–9 perifoveal 
zones. ETDRS=Early Treatment Diabetic Retinopathy Study. OCT=optical 
coherence tomography.
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data were downloaded by study sites when masks were 
returned. The manufacturer was also sent anonymised 
data from every returned light mask to measure 
compliance. We took the pragmatic decision that 6 h/day 
(4380 h over 2 years) was sufficient to represent 100% 
compliance and, therefore, represented the level at and 
above which maximum benefit would be derived. 
We defined compliance as patients who wore the masks 
70% of the time (3066 h, counting time truncated to 
6 h/day). If compliance data were missing for a day then we 
assumed no compliance (ie, the mask had not been worn 
that night).  
The trial manager contacted study sites to request they 
take steps to maximise the rate of mask return, to ensure 
availability of compliance data. The trial manager followed 
the trial monitoring plan by undertaking off-site moni-
toring on a monthly basis. This process included contacting 
sites at which patients’ compliance was less than 40%. The 
manufacturer also alerted the trial manager when patients 
had poor compliance. Moreover, during every on-site 
monitoring visit, sites were asked to reinforce with patients 
the importance of wearing the masks every night during 
sleep, and specific patients with issues of compliance were 
discussed. The Data Monitoring Committee, in closed 
meetings, reviewed the accumulating compliance data and 
concluded that a dose-effect of the light masks should also 
be evaluated by comparing the effect of the light masks at 
three levels of compliance (50%, 60%, and 70%). The 
protocol was amended to this effect and approved by the 
Trial Steering Committee, the sponsor, and the Research 
Ethics Committee.
The clinical assessments schedule is detailed in the 
appendix (p 1) and in the published protocol.11 We recorded 
HbA1c at baseline, 12 months, and 24 months. Patients had 
OCT assessments every 4 months, and these assessments 
were done twice at 12 months and 24 months to ensure that 
the treatment effect was distinguished from the test-retest 
variability. We recorded concomitant diabetic medications, 
anti-VEGF agents, steroids, and laser treatment throughout 
the study. We measured refracted best-corrected visual 
acuity at baseline, 12 months, and 24 months using 
validated ETDRS visual acuity charts, and we repeated 
these measurements at baseline to assess test-retest 
variability. We did three-field colour fundus photography at 
baseline, 12 months, and 24 months to grade the severity of 
diabetic retinopathy. Both the examining clinician and 
graders at the independent reading centre graded 
anatomical charac teristics of the diabetic macular oedema 
and severity of diabetic retinopathy. We defined an 
improvement in severity score for diabetic retinopathy as 
the proportion of patients with an ETDRS severity level 
of 2 or higher, at 12 months and 24 months (appendix pp 2, 3). 
We measured sleep disturbances at 12 months and 
24 months. We used the Epworth Sleepiness Scale (ESS) to 
assess changes in daytime sleepiness, with scores ranging 
from 0 (low level of daytime sleepiness) to 24 (high level of 
daytime sleepiness),12 and the Pittsburgh Insomnia Rating 
Scale—20 item version (PIRS-20) to assess changes in 
insomnia, with scores ranging from 0 (no insomnia) to 
60 (worse insomnia).13
We recorded adverse events at every visit. We analysed 
differences from baseline to 24 months in ocular and 
systemic safety profiles with the light mask relative to the 
sham mask. Two clinicians who were unaware of treatment 
allocation coded ocular and systemic adverse events.
A subset of patients (n=30) also underwent oximetry, 
multifocal electroretinography, and microperimetry before 
and after 100% oxygen at baseline and 12 months. This 
mechanistic component of the study will be reported later.
Outcomes
The primary outcome was the change from baseline to 
24 months in maximum retinal thickness in the study 
eye with the light mask relative to the sham mask, 
measured by OCT. For participants with the same 
maximum baseline retinal thickness in two zones, the 
zone located in the parafoveal zone was chosen. When 
these two zones were in the parafoveal zone, the average 
retinal thickness was taken in subsequent follow-up 
measurements. For 12-month and 24-month measure-
ments, OCT was done twice and the average of the 
measurements was taken. 
A per-protocol secondary analysis excluded data from 
the point at which any patient was treated for worsening 
diabetic macular oedema. Additional secondary out comes 
assessed at 12 months and 24 months included changes in 
thickness in the central subfield zone, zones 1–5, and 
zones 1–9, total macular volume, and morphological 
characteristics of diabetic macular oedema. We also 
assessed the change in refracted best-corrected visual 
acuity from baseline at 12 months and 24 months. Disease 
progression outcomes included time to occurrence of 
centre-involving diabetic macular oedema (defined as 
>300 μm), the proportion of patients progressing to 
centre-involving diabetic macular oedema of 400 μm 
or greater (ie, they met eligibility criteria for treatment 
with anti-VEGF agents in England and Wales), and the 
number of patients who received standard treatment for 
diabetic macular oedema at 12 months and 24 months 
(including anti-VEGF agents, steroids, and macular laser 
therapy).
Statistical analysis
The pilot for this intervention8 provided an SD for the 
change from baseline in retinal thickness of 35·68 μm 
and informed 20% attrition. The detectable effect size of 
15 µm was plausible relative to the 95% CI, and was 
minimally distinguishable from the 10·2 µm test–retest 
variation, for which the test–retest mean change over 
time of 0·9 µm was adequately small. A sample size of 
300 patients (150 per treatment group)—with 240 patients 
analysed—provided 90% power based on a two-sided, 
unpaired t test at the 5% level of significance. 
Standardised effect sizes of 0·42 between treatment 
See Online for appendix
Articles
www.thelancet.com/diabetes-endocrinology   Published online March 5, 2018   http://dx.doi.org/10.1016/S2213-8587(18)30036-6 5
groups were detectable for secondary outcomes—eg, 
change in visual acuity. The planned statistical analysis 
incorporated serial measures and baseline adjustment, 
ensuring an improvement in power and in the precision 
of estimated treatment effects on each outcome.
We finalised the statistical analysis plan before data 
lock and agreed it with the oversight committees (Trial 
Steering and Data Monitoring Committees). We analysed 
the primary outcome with a linear mixed-effects model, 
incorporating six 4-monthly post-baseline observations of 
the outcome over time to 24 months and accom modating 
the within-participant correlation over time with an 
unstructured covariance matrix.14 The model included 
fixed factors for treatment group, HbA1c, and study site, 
and the continuous baseline of the outcome, each 
interacting with time. We did a sensitivity assessment of 
the missing-at-random assump tion made in the primary 
outcome analysis in all patients, with three recommended 
scenarios affecting either one or both treatment groups, 
making this an intention-to-treat strategy,15,16 with the 
intention-to-treat population compris ing all randomised 
patients with OCT data. We did a per-protocol secondary 
analysis in which we excluded data from randomised 
patients at the point at which they were treated with 
steroids, anti-VEGF agents, or laser therapy, because 
these treat ments could substantially improve retinal 
thick ness after deterioration. We analysed secondary 
continuous outcomes with the same model specification 
as for the primary outcome, and with a missing baseline 
indicator if needed,17 and we reported data as adjusted 
differences in means. All tests were two-sided at the 
5% significance level and effect sizes were inter preted 
cautiously with 95% CIs. We used the t test to compare 
means, the χ² test or Fisher’s exact test for single 
proportions, McNemar’s SE for changes in prop or tions, 
and the Kaplan-Meier test for cumulative proportions.18
We used complier average causal effect (CACE) analysis 
to estimate efficacy in patients who complied with 
treatment. We defined compliance, in turn, as wearing 
the assigned mask 70%, 60%, and 50% of the time, 
assuming the missing-at-random assumption in the 
primary outcome model and no effect of randomisation 
on outcome in non-compliers.19
We did sensitivity analyses of patients who met the 
requirement for treatment of centre-involving diabetic 
macular oedema because the central subfield thickness 
reached 400 µm before the 24-month endpoint, on the 
time to reaching 400 µm, and on the potential differential 
variability in retinal thickness between treatment groups 
(with the Mann-Whitney test). Because Spectralis 
(Heidelberg Engineering, Heidelberg, Germany) is the 
only OCT device with automatic real-time tracking, we 
did a sensitivity analysis including only patients who had 
OCT outcomes captured with this device at baseline. 
We also did a sensitivity analysis to exclude outliers 
defined as 4 SD from expected, which we do not present 
here because no changes were recorded in primary or 
secondary outcome analysis conclusions. We used IBM 
SPSS Statistics version 23 for statistical analyses.
This trial is registered with Controlled-Trials.com, 
number ISRCTN85596558.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The manufacturer of the light mask provided input into 
protocol development and trained site staff to offer the 
light mask as per protocol and their instructions for use 
manual. The manufacturers were sent anonymised data 
from every returned light mask for measurement of 
compliance. They provided feedback to the study team 
on masks that showed low compliance so clinical site 
staff could be informed and asked to reinforce use. The 
statisticians (ATP and JCV) had full access to all data in 
the study and the chief investigator (SS) had final 
responsibility for the decision to submit the results for 
publication.
Results
Between April 10, 2014, and June 15, 2015, 349 patients 
were assessed for eligibility. 41 patients did not meet 
eligibility criteria and were excluded; thus, 308 participants 
144 included in primary outcome linear
mixed-effects model
133 included in primary outcome linear
mixed-effects model
11 had no OCT data available
155 allocated light mask
308 randomised
349 assessed for eligibility
41 excluded
9 central macular oedema
2 clinical deterioration
19 insufficient retinal thickening
3 withdrawal of consent
8 other eligibility criteria not met
153 allocated sham mask
127 had OCT data at 24 months†
28 discontinued
2 died
1 adverse event
12 no longer wished to take part
2 unable to locate or contact
3 other reasons
8 lost to follow-up (unknown reason)
20 had no OCT data available
119 had OCT data at 24 months*
34 discontinued
1 died
19 no longer wished to take part
6 unable to locate or contact
2 images too poor quality
2 other reasons
4 lost to follow-up (unknown reason)
Figure 2: Trial profile
OCT=optical coherence tomography. *Includes four patients lost to follow-up who had clinical OCT data. 
†Includes five patients lost to follow-up who had clinical OCT data.
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were randomly assigned to receive either the light mask 
(n=155) or the sham mask (n=153; figure 2).
Baseline characteristics were well balanced between 
treatment groups (table 1). The mean age of patients was 
57 years (SD 11). 194 (63%) of 308 participants were men. 
286 (93%) had baseline maximum retinal thickness in 
parafoveal zones 2–5 whereas 22 (7%) had maximum 
retinal thickness in perifoveal zones 6–9. 154 (50%) patients 
had HbA1c less than 8% (63·89 mmol/mol) at baseline. 
The average of the two refracted visual acuity measure-
ments at baseline was mean 84·3 (SD 7·3) ETDRS letters, 
which was equivalent to 6/6 Snellen. 183 (59%) of 
308 patients had OCT measurements taken with Spectralis 
(Heidelberg Engineering), 54 (18%) with Cirrus (Carl Zeiss 
Meditec, Cambridge, UK), 61 (20%) with Topcon 2000 
(Topcon, Tokyo, Japan), and ten (3%) with RS3000 (Nidek, 
Aichi, Japan). 62 patients did not have primary outcome 
data (figure 2); no differences in baseline characteristics 
were noted between patients who dropped out and those 
who did not, except for study site, which was already 
adjusted for in the analysis (appendix p 4). This finding 
was attributable largely to one study site having a high 
dropout rate.
For the prespecified primary outcome analysis, OCT 
data were available for 246 (80%) of 308 patients at 
24 months, of whom 127 were assigned the light mask 
and 119 were allocated the sham mask. This number 
includes five patients assigned the light mask and four 
patients allocated the sham mask, for whom OCT data 
were obtained from routine clinical care (ie, the patient 
attended their clinic appointment but did not attend an 
intervening research visit). An additional 17 patients 
assigned the light mask and 14 allocated the sham mask 
Sham mask 
(n=153)
Light mask 
(n=155)
Age (years) 59·0 (51·0–67·0) 57·0 (51·0–65·0)
Sex
Men 92 (60%) 102 (66%)
Women 61 (40%) 53 (34%)
Ethnic origin
White 94 (61%) 100 (65%)
Black 29 (19%) 27 (17%)
Asian 28 (18%) 24 (15%)
Other 2 (1%) 4 (3%)
Smoker 10 (7%) 13 (8%)
Study site
Bristol Eye Hospital 6 (4%) 6 (4%)
Birmingham Heartlands 
Hospital
4 (3%) 7 (5%)
Sandwell & West 
Birmingham Hospitals NHS 
Trust
3 (2%) 3 (2%)
Frimley Park Hospital 16 (10%) 16 (10%)
Hillingdon Hospital 27 (18%) 27 (17%)
King’s College Hospital 17 (11%) 18 (12%)
Moorfields Eye Hospital 25 (16%) 26 (17%)
Central Middlesex Hospital 3 (2%) 1 (1%)
Maidstone & Tunbridge Wells 
Hospital
6 (4%) 6 (4%)
Princess Alexandra Hospital, 
Harlow
6 (4%) 5 (3%)
The Royal Wolverhampton 
NHS Trust
11 (7%) 10 (6%)
Brighton & Sussex University 
Hospitals NHS Trust
1 (1%) 2 (1%)
Sunderland Eye Infirmary 13 (8%) 12 (8%)
Stoke Mandeville Hospital 5 (3%) 5 (3%)
William Harvey Hospital Kent 10 (7%) 11 (7%)
Blood pressure (mm Hg)
Systolic 140·3 (18·9)* 137·2 (16·5)*
Diastolic 81·0 (10·2)* 80·2 (9·4)*
Diabetes mellitus
Type 1 20 (13%) 31 (20%)
Type 2 133 (87%) 124 (80%)
(Table 1 continues in next column)
Sham mask 
(n=153)
Light mask 
(n=155)
Continued from previous column
Medication
Insulin only 22 (14%) 43 (28%)
Oral hypoglycaemic agents 
only
75 (49%) 72 (46%)
Insulin and oral 
hypoglycaemic agents
56 (37%) 39 (25%)
Diet-controlled 0 1 (1%)
Best-corrected visual acuity 
(ETDRS letters)
86·0 
(81·3–89·0)
85·5 
(81·5–89·0)
Maximum retinal thickness 
(µm)
348·8 (24·3) 345·9 (21·6)
Total volume (mm³) 8·7 (8·3–9·3) 8·7 (8·3–9·2)
HbA1c
<8% (<63·89 mmol/mol) 77 (50%) 77 (50%)
≥8% (≥63·90 mmol/mol) 76 (50%) 78 (50%)
Severity level (study eye)†
10 2 (1%) 2 (1%)
20 25 (17%) 35 (23%)
35 101 (69%) 93 (60%)
43–47 11 (7%) 15 (10%)
53 0 1 (1%)
61‡ 0 2 (1%)
65‡ 1 (1%) 1 (1%)
71–75‡ 0 1 (1%)
81–85‡ 0 0
90‡ 7 (5%) 4 (3%)
Intraocular pressure (mm Hg) 16·0 
(14·0–18·0)*
16·0 (14·0–18·0)§
Data are median (IQR), mean (SD), or number of participants (%). ETDRS=Early 
Treatment Diabetic Retinopathy Study. *Data missing for one participant. 
†Data from the independent reading centre; data missing for five participants 
assigned the sham mask and one allocated the light mask. ‡Participants with these 
severity levels should have been excluded. §Data missing for two participants.
Table 1: Baseline characteristics
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had OCT data from previous timepoints (appendix p 5). 
Therefore, 277 (90%) of 308 patients were included in the 
intention-to-treat linear mixed-effects model, of whom 
144 had been assigned the light mask and 133 had 
been allocated the sham mask. At 24 months, in the 
246 patients who had data available, no difference was 
recorded in mean change in maximum retinal thickness 
between the light mask and sham mask (adjusted 
difference –0·65 µm, 95% CI –6·90 to 5·59; p=0·84; 
table 2). Furthermore, no difference was noted in mean 
change in maximum retinal thickness between treatment 
groups at any timepoint (appendix p 6).
For the per-protocol secondary analysis of change in 
maximum retinal thickness, in which patients were 
excluded at the point they began treatment for diabetic 
macular oedema (laser therapy, steroids, or anti-VEGF 
agents; appendix p 7), 266 patients were included in the 
linear mixed-effects model at 12 months and 24 months 
(the linear mixed-effects model takes into account data at 
all timepoints).  56 patients needed treatment for diabetic 
macular oedema, of whom 23 had been assigned the light 
mask and 33 had been allocated the sham mask. The 
difference in the cumulative proportion of patients 
requiring treatment between treatment groups was 
8% (95% CI 0–16) at 12 months and 9% (1–18) at 24 months. 
The change in maximum retinal thickness did not differ 
between the light mask and sham mask at 12 months and 
24 months (adjusted difference at 24 months 3·23 µm, 
95% CI –2·11 to 8·58; p=0·23; appendix p 8).
Median compliance with wearing the light mask 
was 39·5% (IQR 9·8–78·2) at 4 months, falling to 
19·5% (1·9–51·6) at 24 months. When considering the 
three definitions of compliance (ie, 70%, 60%, and 50%, 
with 70% compliance meaning the light mask was used 
70% of the available time in the study, up to 6 h/day 
counted daily), the proportions of patients achieving each 
of these three levels of compliance decreased over time 
(appendix p 9).
Sensitivity analyses for missing data were done to 
represent three possible scenarios, to reflect whether 
departures from the missing-at-random assumption 
applied within patients assigned the light mask only, 
within those allocated the sham mask only, and within 
both treatment groups equally and in the same direction 
(appendix p 10). The change in maximum retinal thickness 
did not differ between use of the light mask and the sham 
mask for all three scenarios. Assuming patients with 
unobserved outcome data in one or both treatment groups 
would take values as much as a prespecified 20 µm either 
side of the adjusted observed effect, all 95% CIs 
included 0 and excluded –15, thus confirming that the 
absence of a clinically important light mask effect is robust 
to missing data (appendix p 11). In the sensitivity analysis 
for non-compliance, the CACE estimate for compliers 
defined by 70% compliance was –4·2 (95% CI 
–44·6 to 36·1), 60% compliance was –3·1 (–32·4 to 26·3), 
and 50% compliance was –2·5 (–26·7 to 21·7). Across 
these three definitions of compliers, the results were 
consistent in estimating a small non-significant inter-
vention effect, which was not close to the detectable effect 
of 15 μm retinal thickness.
In the sensitivity analysis of patients who met the 
requirement for treatment of centre-involving diabetic 
macular oedema (ie, retinal thickness reached 400 µm 
before the 24-month endpoint), the retinal thickness 
measurement taken just after the participant first reached 
400 µm was carried forward to be their final measurement. 
Nine patients achieved 400 µm in central macula, of whom 
three had been assigned the sham mask (all achieved this 
point at 24 months) and six had been allocated the light 
mask (two achieved this point at 24 months, two at 
20 months, and two at 12 months). 161 patients were 
included in this linear mixed-effects model and the 
adjusted difference between treatment groups was 
–0·22 µm (95% CI –8·36 to 7·92; p=0·96). 259 patients 
were included in the Cox proportional hazards regression 
time-to-event analysis (ie, time to reaching 400 µm), which 
was stratified by HbA1c (hazard ratio 2·0, 95% CI 0·5–8·0; 
p=0·33). For the sensitivity analysis of potential differential 
variability between the light mask and sham mask over 
time in the zone of maximum baseline retinal thickness, 
which was done in 246 patients, the difference between 
treatment groups was not significant from baseline to 
24 months (p=0·38). A sensitivity analysis of the primary 
outcome in patients who had OCT measurements 
taken with Spectralis (Heidelberg Engineering) at base-
line showed no diff erence between treatment groups 
(appendix p 12).
In the secondary analyses of retinal thickness and 
volume, no significant differences were noted between the 
light mask and sham mask in change from baseline in 
central subfield thickness, total thickness of central and 
parafoveal zones, total retinal thickness measured over all 
nine zones, and total macular volume at 12 months and 
24 months (appendix pp 13, 14). Analysis of secondary 
morphological outcomes showed that signifi cantly more 
Maximum retinal thickness 
(µm)
Mean (SE) change from 
baseline (µm)
Adjusted 
difference 
(95% CI)* (µm)
p value
Sham mask Light mask Sham mask Light mask
Baseline† 348·8 (24·3), 
n=153
345·9 (21·6), 
n=155
.. .. .. ..
12 months 339·1 (35·9), 
n=121
341·3 (29·7), 
n=132
–9·5 (3·1) –4·6 (2·5) 1·73 
(–5·31 to 8·77)
0·63
24 months 336·3 (29·7), 
n=119
336·0 (25·5), 
n=127
–12·9 (2·9) –9·2 (2·5) –0·65 
(–6·90 to 5·59)
0·84
Data are mean (SD), number of participants, unless otherwise indicated. 277 patients were included in the linear-mixed 
effects model. OCT=optical coherence tomography. *Adjusted for HbA1c, study site, and baseline maximum retinal 
thickness. †Mean maximum baseline retinal thickness for 133 patients assigned the sham mask and included in the linear 
mixed-effects model was 348·6 µm (SD 24·2) and for 144 patients allocated the light mask it was 345·4 µm (21·2). 
Mean maximum baseline retinal thickness for 20 patients assigned the sham mask and not included in the model was 
350·6 µm (SD 25·6) and for 11 patients allocated the light mask it was 352·9 µm (26·6).
Table 2: Maximum retinal thickness measured by OCT at baseline, 12 months, and 24 months
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patients assigned the light mask had resolution of diffuse 
diabetic macular oedema at 12 months (difference between 
groups in change from baseline, –13%, 95% CI –23 to –2; 
p=0·0246), but this effect was lost at 24 months (2%, 
–10 to 14; p=0·75). Foveal cysts were somewhat reduced at 
12 months (–12%, 95% CI –25 to 0·1; p=0·052) and 
24 months (–14%, –27 to 0·3; p=0·054) in patients assigned 
the light mask compared with those allocated the sham 
mask. Changes in visible cysts in the inner ETDRS zones 
did not differ between treatment groups but the proportion 
of patients with visible cysts in the outer ETDRS zones was 
reduced significantly more in patients assigned the light 
mask compared with those allocated the sham mask 
(appendix pp 15, 16).
The adjusted difference in best-corrected visual acuity 
between the light mask and sham mask was also not 
significant (at 12 months, –0·07 ETDRS letters, 95% CI 
–1·38 to 1·23; p=0·91; at 24 months, 0·13 ETDRS letters, 
–1·45 to 1·71; p=0·87; appendix pp 13, 14). The proportion 
of patients showing progression of retinopathy was low, 
and no difference was recorded between treatment groups 
at 12 months and 24 months (appendix p 17). With respect 
to sleep disturbances, ESS scores and PIRS-20 scores did 
not differ between treatment groups (appendix pp 13, 14).
The success of concealing the treatment allocation from 
primary assessors (OCT technicians and optometrists) 
was assessed with a guess form. In line with chance, 
OCT technicians guessed the allocation correctly for 
137 (55%) of 248 patients and optometrists for 129 (52%) of 
246 patients. The response was based on random choice 
for 180 (73%) OCT technicians and 231 (94%) optometrists, 
and 68 (27%) and 15 (4%), respectively, made an educated 
guess based on a clinical response or adverse event.
58 serious adverse events were recorded, of which 
32 were reported in patients assigned the light mask and 
26 were noted in those allocated the sham mask; none 
were related to the active intervention (appendix p 18). 
340 adverse events not related to the intervention were 
reported, of which 172 were noted in patients assigned 
the light mask and 168 were in those assigned the sham 
mask (appendix p 19). 72 adverse events were reported as 
related to the assigned treatment, which included 
50 in patients allocated the light mask and 22 in those 
assigned the sham mask (table 3). The most frequent 
adverse events related to the assigned treatment were 
discomfort on the eyes (14 with the light mask vs seven 
with the sham mask), painful, sticky, or watery eyes 
(14 vs six), and sleep disturbance (seven vs one).
Discussion
The CLEOPATRA trial is the first phase 3 randomised 
controlled trial to evaluate a light mask as an intervention 
to treat and prevent non-central diabetic macular oedema 
in a multicentre setting. Our results show that the light 
mask as offered in this study is not an effective option in 
the treatment or prevention of progression of non-central 
diabetic macular oedema. Although objective assessment 
of the reduction of maxi mum retinal thickness was our 
primary outcome, we have made our conclusion based on 
the primary outcome, per-protocol secondary analysis, and 
five prespecified sensitivity analyses of the primary 
outcome, and none of these analyses showed any 
therapeutic benefit of wearing these light masks. Moreover, 
because of the dynamic nature of diabetic macular oedema, 
we considered several secondary outcomes, including 
reduction in total retinal thickness, macular volume, 
progression of central subfield thickness to 300 µm or 
more, and the proportions of patients requiring treatment 
for new onset centre-involving diabetic macular oedema 
and of those treated with standard therapy during the trial 
due to worsening of diabetic macular oedema. None of the 
changes in these variables was significant between 
treatment groups, substantiating the results of the primary 
outcome. Furthermore, no treatment effect was noted in 
severity of diabetic retinopathy with these light masks. 
However, the light masks did significantly reduce diffuse 
diabetic macular oedema and visible cysts in outer ETDRS 
zones at 12 months, but this effect did not translate to a 
signifi cant change in retinal thickness and the effect was 
not sustained at 24 months, suggesting that any positive 
morphological effects of these light masks on diabetic 
macular oedema is transient and minimal.
We expected compliance with light masks to be an 
issue based on findings of the phase 2 study10 and 
because non-centre-involving diabetic macular oedema is 
Sham mask 
(n=153)
Light mask 
(n=155)
Eyes
Corneal abrasion, corneal ulcer 3 0
Mask causing pressure on eyes, pain on eyes, 
uncomfortable masks
7 14
Sore eyebrows, sore eyelids 0 2
Subconjunctival haemorrhage 0 1
Vision deterioration, disturbance 1 2
Watery eyes, sore eyes, sticky eyes, 
painful eyes, conjunctivitis
6 14
Neurological
Headache, severe persistent headache 0 2
Psychiatric
Insomnia 0 1
Musculoskeletal
Left-sided neck and skull pain 0 1
Dermatological
Scratched face on two occasions getting 
mask off during sleep
1 0
Sore skin, small lump on side of right eye 0 1
Pod moving around in mask when turns in bed 0 1
Wart 0 1
Other
Mask slipping off head 3 3
Sleep disturbance, bad dreams 1 7
Table 3: Adverse events related to intervention
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asymptomatic. Therefore, we made several efforts to 
tackle compliance-related issues in this study. First, 
we calculated the sample size with a 20% attrition rate, 
which is higher than most ophthalmic trials. Furthermore, 
we allowed for OCT measurements from clinic appoint-
ments to be used when patients attended the clinic visit 
and not a clinical trial visit appointment. We had also 
carefully considered the effect of non-compliance on the 
potential therapeutic effect of the light masks by 
incorporating a predefined CACE analysis for non-
compliance at three levels—70%, 60%, and 50%. 
Non-compliance was noted as early as 4 months into the 
trial and across all three definitions of compliance. 
Compliance with use of light masks has varied between 
studies and can be partly explained by  the differences in 
definitions used in determining compliance levels.10,20–23 
However, this study is the first randomised trial evaluating 
the use of a light mask during sleep at night over 
24 months and shows that compliance reduces over time 
in keeping with the adherence patterns of self-
management strategies in asymptomatic diabetes.24 
Decline in adherence is rapid after the first 6 months of 
therapy in chronic diseases.25 The compliance levels 
observed in our study are in keeping with the WHO 
report25 that shows that the mean adherence to long-term 
therapy in patients with chronic diseases is approximately 
50%. Therefore, further studies should include additional 
interventions to increase patient engagement in wearing 
the light masks to evaluate whether this intervention is 
sustainable over the lifetime of their diabetic eye disease. 
Both treatment groups showed a gradual mean 
reduction in the zone of maximum retinal thickness over 
24 months. The reduction is within the SD that we used 
for the sample size calculation. The event rate of 
progression to centre-involving diabetic macular oedema 
was also similar to findings of previous reports.2,5
The main strength of our study was that we ensured that 
the primary outcome was corroborated by a predefined 
sensitivity analysis and secondary analysis to reduce 
potential systemic biases in this dynamic condition. Other 
strengths included clear definition of objective endpoints, 
publication of the protocol, substantial public and patient 
involvement throughout the study, and strict assessment-
assured high-quality data and preplanned analysis for 
expected non-compliance. The baseline characteristics of 
the trial population were typical for the intended patient 
population. The representative multiethnic patient popul-
ation, together with the multicentre trial design, permit 
wide generalisability of our results.
Nevertheless, some limitations should be considered 
when interpreting the results. First, the study only shows 
that offering the light mask as per this study protocol to 
suppress rod function is not an effective option to treat 
non-central diabetic macular oedema. It is possible that 
the retinal illumination achieved with these devices did not 
reduce the dark current sufficiently to alter the hypoxic 
state. Therefore, it is worth evaluating other techniques of 
rod suppression in diabetic retinopathy and diabetic 
macular oedema since there is a growing body of scientific 
evidence that supports the role of photoreceptors in retinal 
vascular permeability and angiogenesis.26,27 Other clinical 
trials of light masks to prevent dark adaptation in diabetic 
retinopathy are ongoing. The Lahey Light II trial20 (LCID 
Study Number 2015-020) is evaluating a modified 520 μm 
LED light mask to prevent dark adaptation in refractory 
diabetic macular oedema.  Two other clinical trials 
(ISRCTN82148651 and NCT02207712) are ongoing for age-
related macular degeneration. However, it is important 
that studies with long-term follow-up are conducted in 
these chronic conditions to provide further insight into 
this intervention. Second, it could be argued that hypoxia 
might not be a contributing factor in early diabetic macular 
oedema and that patients with early signs of this disorder 
might not be the ideal target population. However, oxygen 
therapy has been shown to ameliorate early diabetic 
macular oedema, reinforcing the role of hypoxia in this 
condition.9,28 A third limitation is that we defined non-
centre-involving diabetic macular oedema as a zone of 
retinal thickness above 320 µm. Although the normative 
data of some zones on Spectralis OCT could in fact be 
above 320 µm, we only included eyes with clinical evidence 
of diabetic macular oedema causing the retinal thickness 
to be greater than 320 µm. Therefore, we believe that our 
patient population is representative of early non-central 
diabetic macular oedema. In our study, there was no 
discernible treatment effect in favour of the light mask at 
4 months and 8 months when compliance was highest; in 
fact, any effect was in the opposite direction, which was 
maintained at 12 months, suggesting that low compliance 
did not contribute significantly to the overall study result.
In conclusion, the light mask as offered in this study is 
not an effective intervention to prevent or treat patients 
with non-centre-involving diabetic macular oedema. 
Future trials should aim to identify better ways of rod 
suppression to assess the role of rods in diabetic macular 
oedema and diabetic retinopathy.
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